CEFO Co., Ltd. develops allogeneic, off-the-shelf cell therapies targeting bone diseases in aging populations. Leveraging umbilical cord-derived stem cells with a proven safety record, CEFO has built a proprietary 3D differentiation platform to generate musculoskeletal tissues including bone, cartilage, fat, and muscle. This technology enables rapid osteogenic differentiation, reduced culture time, and scalable production, and is protected by patents covering 3D hydrogel-based culture and manufacturing methods. CEFO’s cryopreserved formulation allows long-term storage and global cold-chain distribution, ensuring product stability and reproducibility. Compared with autologous therapies, CEFO’s allogeneic approach offers superior scalability, cost-effectiveness, and immediate availability. By integrating innovation across cell sourcing, differentiation, and manufacturing, CEFO is advancing a next-generation regenerative platform that is effective, reliable, and globally accessible.

CEFO Co., Ltd. has conducted a performance evaluation of STeMiN® as a cosmetic raw material. It has secured patents for whitening, regeneration, wrinkle improvement, and immune suppression. It has also completed evaluations of various toxicities and safety, including skin sensitization, by the MFDS guidelines.